← Back to Clinical Trials
Recruiting NCT06729437

NCT06729437 Transcranial Direct Current Stimulation on Functionality and Pain in Individuals with Patellar Tendinopathy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06729437
Status Recruiting
Phase
Sponsor University of Valencia
Condition Patellar Tendinopathy
Study Type INTERVENTIONAL
Enrollment 42 participants
Start Date 2024-07-01
Primary Completion 2027-07-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
tDCS + Therapeutic eccentric exerciseSham tDCS + Therapeutic eccentric exercise

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 42 participants in total. It began in 2024-07-01 with a primary completion date of 2027-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of the present study is to investigate the effectiveness of transcranial direct current stimulation (tDCS) prior to a therapeutic eccentric exercise program on parameters related to pain and functionality in individuals with patellar tendinopathy. For this purpose, participants will be randomly divided into two groups: i) experimental group, receiving tDCS prior to a therapeutic exercise program; and ii) control group, receiving sham tDCS and a therapeutic exercise program. The interventions will last for 8 weeks. Additionally, four assessments will be conducted (baseline, week 4, week 8 and week 12). The variables studied are related to pain, functionality, muscle activity and strength, proprioception, and quality of life.

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 50 years. * Diagnosis of patellar tendinopathy (VISA-P score of 80 or lower). * Pain lasting more than 3 months. Exclusion Criteria: * Previous knee surgery. * Corticosteroid injection in the previous 6 weeks. * Systemic inflammatory, autoimmune, or rheumatic diseases. * Cognitive or behavioural issues that hinder comprehension and adherence to the intervention. * Any neurological disease. * Neoplastic disease. * Subjects presenting contraindications for tDCS (Thair et al., 2017), including: personal and family history of epilepsy, metallic implants in the head, implanted medication pump, pacemaker, recurrent headaches, skin conditions (psoriasis, eczema), or major head surgeries, pregnancy, heart diseases, and various medications (psychotropic or antihistamines). * Subjects must not have undergone pharmacological treatment or knee physical rehabilitation programs for a period of 1 year.

Contact & Investigator

Central Contact

Marta Inglés, Dr

✉ marta.ingles@uv.es

📞 963 98 38 55

Principal Investigator

Marta Inglés, Dr

PRINCIPAL INVESTIGATOR

Univeristy of Valencia

Frequently Asked Questions

Who can join the NCT06729437 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Patellar Tendinopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06729437 currently recruiting?

Yes, NCT06729437 is actively recruiting participants. Contact the research team at marta.ingles@uv.es for enrollment information.

Where is the NCT06729437 trial being conducted?

This trial is being conducted at Valencia, Spain.

Who is sponsoring the NCT06729437 clinical trial?

NCT06729437 is sponsored by University of Valencia. The principal investigator is Marta Inglés, Dr at Univeristy of Valencia. The trial plans to enroll 42 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology